Seòmar agus comataidhean

My officials engage with the pharmaceutical industry on a range of matters, including the development of new medicines, and keep me updated as required.

The Chief Pharmaceutical Officer last met with Vertex Pharmaceuticals on 6 December 2023 and continued to impress upon them the importance of offering a revised price to address the concern that the current price of the cystic fibrosis (CF) medicines covered by the multiple technology appraisal (MTA) exceeds what the NHS would consider reasonable. She also discussed the ongoing availability of clinical trial CF medicines, including when a trial is stopped.

I refer the member to the answer to question S6W-23384 on 11 December 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

My officials engage with the UK Government on a range of medicines-related matters, including the availability of medicines, and keep me updated as required.

The National Institute for Health and Care Excellence (NICE) multiple technology assessment (MTA) final guidance is currently expected to be published on 20 March 2024.

As the Scottish Medicines Consortium (SMC) is partnering with NICE in the assessment of these medicines, the SMC will publish recommendations aligned with the final NICE guidance thereafter for Health Boards in Scotland to consider.

The Scottish Government remains committed to supporting people with cystic fibrosis (CF) to benefit from medicines which help them to live fuller lives, for longer. That is why we introduced a memorandum of understanding (MoU) with the manufacturer, Vertex Pharmaceuticals, in 2018. As part of the MoU, there was an expectation that Vertex would resubmit each of their CF medicines to the Scottish Medicines Consortium (SMC) for a health technology appraisal (HTA). To progress this, the SMC is collaborating with the National Institute for Health and Care Excellence (NICE) on a multiple technology appraisal (MTA) of Vertex’s CF medicines, including Kaftrio ® .

While the NICE MTA is ongoing, I can confirm that all existing and new patients in Scotland who are on, or who are started on a CF medicine will continue to have access to that CF medicine after NICE and the SMC issue their final recommendations. This will be irrespective of the outcome of the appraisal and will cover any need to subsequently switch to a different CF medicine.

If any CF medicine is not recommended in the final MTA guidance, clinicians in Scotland will be able to request the use of that medicine on a case-by-case basis for any new patients using the Peer Approved Clinical System (PACS) Tier Two process. National guidance explicitly states that Health Boards should not take account of the cost of medicines when considering applications using the PACS Tier Two system.

We recognise the significant impact on people, businesses and communities in areas affected by storm Babet. The Scottish Government is committed to playing its part in helping them through this horrible experience which has destroyed so many people’s property and belongings.

We recognise the significant impact on people, businesses and communities in areas affected by storm Babet. The Scottish Government is committed to playing its part in helping them through this horrible experience which has destroyed so many people’s property and belongings.

The number of Expansion Posts created in 2023 was not impacted by the reprofiling of the Health Workforce Expansion Posts budget line, as set out in the letter from the Cabinet Secretary for Finance to the Finance and Public Administration Committee of 21 November 2023. The number of postgraduate specialty training expansion posts to be added in 2023 was set by Scottish Ministers in late 2022, on the basis of recommendations from the Scottish Shape of Training Transitions Group.

The Expansion Posts budget line was reprofiled in 2023, following the budget setting process for the 2023-24 financial year. The number of specialty training expansion posts being recruited to was not amended as a result of the reprofiling of this budget line. The budget was reprofiled in accordance with the application of directorate savings targets in the 2023-24 financial year; £3 million was the savings target for Health Workforce, with the saving being applied to the Expansion Posts line for budgeting and accounting purposes. The savings target was applied to this line as historically the forecast budget for Expansion Posts has exceeded actual costs incurred in year.

We are developing a new palliative care strategy to achieve the very highest standards of care right up to the end of life, and to ensure high-quality palliative care wherever and whenever it is needed.

As part of work being undertaken to develop the strategy, we are working with Public Health Scotland to get a better understanding of population-level palliative care needs, now and in the future. This includes consideration of the research that has been carried out by Marie Curie.

As part of work being undertaken to develop the new palliative care strategy, we are working with Public Health Scotland to get a better understanding of population-level palliative care needs now and in the future, both nationally and locally.

We are working with local health and social care partnerships to identify how best we can support a local population based approach to palliative care, so that everyone can access specialist and general palliative care as needed by each person, whatever their illness or condition.

The Primary Care Reform and Delivery Budget total was £262,500,000 in 2023-2024.

Reductions, slippage and reprofiling has taken place across a variety of programmes focused on GP workforce, sustainability, rural healthcare, data and digital improvements.